Does Kevzara Cause Low Neutrophils?
Yes, Kevzara (sarilumab) can cause low neutrophils, a condition known as neutropenia. This is a known side effect listed in its prescribing information and clinical data. Neutrophils are white blood cells that fight infection, and levels below 1,000 cells/mm³ are considered low, with severe cases under 500 cells/mm³.[1]
How Common Is Neutropenia with Kevzara?
In clinical trials for rheumatoid arthritis, neutropenia occurred in 10-15% of patients on Kevzara, dose-dependently. Grade 3 (500-1,000 cells/mm³) affected about 6-12%, and Grade 4 (<500 cells/mm³) hit 1-3%.[1] Rates were higher with the 200 mg dose versus 150 mg. Most cases were reversible upon dose reduction or pausing treatment.
Why Does It Happen and When?
Kevzara blocks IL-6 receptors, reducing inflammation but also suppressing bone marrow production of neutrophils. Low counts often appear within weeks of starting, peaking early, and may worsen with infections or concurrent drugs like methotrexate.[1][2] Monitoring requires complete blood counts before starting, every 4-8 weeks initially, then less often if stable.
What Happens If Neutrophils Drop Too Low?
Mild drops rarely cause issues, but severe neutropenia raises infection risk, including serious ones like pneumonia. FDA warnings note potential for fatal infections; hold Kevzara if absolute neutrophil count (ANC) falls below 500 cells/mm³ until recovery.[1] Symptoms to watch: fever, chills, sore throat, or unusual fatigue.
How Does This Compare to Other RA Drugs?
Kevzara's neutropenia rate exceeds TNF inhibitors like Humira (under 1%) but aligns with other IL-6 blockers. Actemra (tocilizumab) shows similar 10-20% incidence.[2] JAK inhibitors like Xeljanz have comparable or slightly higher rates (up to 20%).[3]
Management and Patient Advice
Doctors adjust doses: reduce to 150 mg if ANC 500-1,000, or stop if lower. Avoid if ANC <2,000 at baseline. No Kevzara-specific patents tie to this side effect; generics aren't available yet (patents expire around 2032).[4] Report symptoms immediately; alternatives like Rituxan may suit high-risk patients.
[1]: Kevzara Prescribing Information (FDA)
[2]: Actemra Prescribing Information (FDA)
[3]: Xeljanz Prescribing Information (FDA)
[4]: DrugPatentWatch.com - Kevzara Patents